A murine model of bacteremic Haemophilus influenzae type b pneumonia was used to evaluate the therapeutic efficacies of the quinolone antimicrobial agents enoxacin and ofloxacin compared with those of ampicillin and chloramphenicol. Ampicillin-susceptible (AS) and ampicillin-resistant (AR) challenge strains were employed. Treatment with enoxacin or ofloxacin produced intrapulmonary killing of H. influenzae that was superior to that achieved with ampicillin (P < 0.01 to P < 0.001 for both AS and AR strains). Ofloxacin and enoxacin also provided killing greater than that with chloramphenicol for the AS strain (P < 0.01 to P < 0.001). For the AR strain, ofloxacin provided killing greater than that obtained with chloramphenicol (P < 0.001). Survival from AS strain pneumonia was 60% in enoxacin-treated and 78% in ofloxacin-treated animals compared with 41% for chloramphenicol-treated and 23% for ampicillin-treated groups. We conclude that enoxacin and ofloxacin may be effective antimicrobial agents in treating either AS or AR strains causing H. influenzae pneumonia.
Haemophilus influenzae is a frequent pulmonary pathogen and may cause life-threatening, invasive pneumonia (1, 5, 8-10, 14, 16) . Results of recent studies suggest that the incidence of H. influenzae pneumonia among adults is increasing (5, 8, 16) . With reported mortalities for this infection ranging from 33 to 57% (8, 16) , studies to describe optimal therapy are well justified. Although ampicillin continues to be an important therapeutic agent for the treatment of serious H. influenzae respiratory infections, alternative therapeutic agents are needed for use in ampicillin-intolerant individuals and also for the treatment of P-lactamaseproducing strains of H. influenzae (1, 9).
Enoxacin and ofloxacin are members of the quinolone class of antimicrobial agents which have demonstrated considerable in vitro activity against clinical H. influenzae isolates, including most ampicillin-resistant strains. For enoxacin, MICs for 90% of strains tested of 0.12 to 0.25 jig/ml have been reported for a series of H. influenzae isolates (2, 17), while for ofloxacin, MICs for 90% of strains tested of 0.06 to 1.56 jig/ml have been reported (13, 17) .
These in vitro observations suggest that enoxacin and ofloxacin should have considerable efficacy in the treatment of serious H. influenzae respiratory infections and provide initiative for experimental studies to address this issue. We have recently developed a murine model of experimental type b H. influenzae pneumonia in which such studies can be conducted (4) . In this study we employed this experimental model to evaluate the therapeutic efficacy of enoxacin and ofloxacin in the treatment of H. influenzae pneumonia and to compare these efficacies with those of the conventional therapeutic agents ampicillin and chloramphenicol. (7), and the half-life of enoxacin and ofloxacin in mice was calculated, also as described previously (7). Experimental pneumonia. The method used for infecting murine lungs with H. influenzae has been described in detail elsewhere (4) . Briefly, animals were anesthetized by intraperitoneal injection of Brevital (methohexital sodium; Eli Lilly & Co., Indianapolis, Ind.) and suspended vertically by hanging the lower incisor teeth on a wire hook and retaining the upper incisors with a taut rubber band. The oropharynx was transilluminated, and under direct visualization the trachea was cannulated with a blunt-tipped metal spinal needle (22 gauge), to which a microliter syringe containing the bacterial suspension was attached. After 40 p.l of the suspension (approximately 109 CFU) was delivered into the trachea, the cannula-syringe apparatus was removed. The animals were maintained in a vertical position for 2 to 4 min and then placed at an angle of 450 until they were awake.
MATERIALS AND METHODS

Animals
To evaluate relative efficacies of study drugs for intrapulmonary killing of bacteria, animals were treated with s.c. injections of enoxacin or ofloxacin (20 mg/kg) at 6 and 18 h after infection, or ampicillin (100 mg/kg) or chloramphenicol (50 mg/kg) at 6, 10, 14, and 18 h after infection. Control animals received four s.c. injections of 0.1 ml of isotonic saline. At 24 h after infection animals were killed with CO2 and by cross-clamping of the trachea (for the prevention of agonal aspirations). The thorax was opened and heart blood was removed for culture. The thoracic contents were removed in toto, and the lungs were dissected free from the trachea and other structures and homogenized in 15 ml Lung to serum ratio of enoxacin and ofloxacin. Lung penetration characteristics for the quinolone agents were determined at two separate time points after therapy. For the study, animals were given a single s.c. injection of enoxacin or ofloxacin and were then sacrificed at two different time intervals after injection. Serum was obtained by direct heart aspiration (as described above). Lungs were made oligemic by perfusion of the right ventricle with isotonic saline (4), removed, and homogenized in fivefold dilutions of isotonic saline (Polytron, Westbury, N.Y.). Enoxacin and ofloxacin concentrations in serum and lungs were determined by using reversed phase high-pressure liquid chromatography, and serum to lung concentration ratios were calculated by using lung concentrations adjusted for the dilution factor (x 5).
Statistics. Data were analyzed by the two-tailed Student t test and the x2 test with the Yates's correction. P values of < 0.05 were considered significant.
RESULTS
In vitro and pharmacokinetic studies. Enoxacin and ofloxacin displayed high in vitro activities against both strains AR and AS of H. influenzae (Table 1) . Enoxacin and ofloxacin dosages of 20 mg/kg resulted in peak concentrations in serum well above the MIC and MBC for the challenge strains. Based on these results the quinolones were employed in dosages of 20 mg/kg for the therapeutic trials. The dosages selected for ampicillin and chloramphenicol were those employed previously in this model (4) .
Therapeutic efficacy in experimental pneumonia. All antibiotic regimens produced intrapulmonary killing of H. influenzae that was significantly greater than that observed in the control group (Table 2) . Except for ampicillin treatment of strain AR, each regimen also reduced the incidence of bacteremia. The two quinolone agents were particularly effective in these studies. For strain AS, both antimicrobial agents demonstrated intrapulmonary killing that was significantly greater than that achieved with ampicillin or chloramphenicol. For strain AR, both quinolone agents provided killing superior to that with ampicillin, and for ofloxacin the killing was also superior to that with chloramphenicol.
To assess the therapeutic efficacies of study drugs over longer treatment periods and to provide confirmation of the lung clearance data, survival studies were carried out with strain AS. All treatment regimens prolonged survival from pneumonia compared with the control group ( b Greater than treatment groups (P < 0.01 to 0.001). c Greater than other treatments (P < 0.01 to 0.001). d Greater than enoxacin (P < 0.01). e Greater than ofloxacin (P < 0.001).
least effective, the quinolone agents were most effective, and chloramphenicol was intermediate in therapeutic efficacy (Table 3) . Lung to serum enoxacin and ofloxacin concentration ratios. We speculated that the high therapeutic efficacy of the quinolones may have resulted from efficient penetration into lung tissues. Accordingly, the drug concentration in lungs was determined and compared with the concomitant concentrations in serum. Because it was necessary to dilute and homogenize lungs for these assays, we utilized enoxacin and ofloxacin injections of 50 mg/kg. A total of 10 animals were studied at each time point for each drug. Mean (+ standard error of the mean) concentrations (in micrograms per milliliter) in serum for enoxacin were 3.49 + 0.57 (1 h) and 0.60 + 0.10 (4 h). For lungs the corresponding concentrations were 9.06 ± 1.74 and 1.31 + 0.31. Lung to serum ratios for enoxacin were thus 2.59 at 1 h and 2.18 at 4 h after the injections. For ofloxacin concentrations in serum were 7.57 + 0.32 (1 h) and 0.71 + 0.10 (4 h), while concentrations in lungs were 5.92 + 0.91 (1 h) and 1.00 ± 0.35 (4 h ). Lung to serum ratios for ofloxacin were 0.78 (1 h) and 1.40 (4 h).
DISCUSSION
Results of recent experimental studies suggest that quinolones are effective therapeutic agents for the treatment of certain respiratory infections. These studies used animal models of acute and chronic Pseudomonas aeruginosa pneumonia (6, 7), as well as Legionella pneumophila pneumonia (12) . Although H. influenzae is a particularly common respiratory pathogen in humans (14) , only limited clinical data are currently available to define the relative efficacy of quinolones compared with established antibiotics for the treatment of life-threatening H. influenzae pneumonia. Accordingly, we conducted a therapeutic trial of enoxacin and To date limited published data are available regarding pulmonary distribution of quinolone agents. Recent published reports with animal models, however, suggest that these agents penetrate lung tissues well (11, 12) . We speculate that the high therapeutic efficacy of quinolones in this study may be related to rapid and efficient penetration into lungs. The high lung to serum ratios observed for enoxacin and ofloxacin in this study (range, 0.77 to 2.74) are consistent with this possibility.
The eventual clinical role of enoxacin and ofloxacin in the treatment of serious H. influenzae respiratory infections remains to be defined. Furthermore, the unpredictable susceptibilities of non-H. influenzae respiratory pathogens (e.g., Streptococcus pneumoniae) to quinolones do not allow for extrapolation from the present data to generalizations on the treatment of pneumonia. Nevertheless, the encouraging observations made in this study do provide rationale for clinical trials of these quinolone agents in the treatment of advanced forms of H. influenzae respiratory infections, including acute pneumonia.
